Moira McMahon REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 MOIRA MCMAHON, Johns Hopkins University, Baltimore The hepatitis B drug ente
Moira McMahon
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007MOIRA MCMAHON, Johns Hopkins University, BaltimoreThe hepatitis B drug entecavir appears to select for a drug resistant HIV mutation – and this has implications for patients infected with both viruses. Derek Thorne got the details fromMoira McMahonfrom Johns Hopkins University in Baltimore. .
Related Episodes
Which HIV Treatment is Best for Patients with HIV and Hepatitis C?
Juan Berenguer REFERENCE: Abstract V-1385, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JUAN BERENGUER, Hospital Gregorio Marañón, Madrid A ret
Monoclonal Antibody to Help Treat HIV?
Jeffrey Jacobson REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JEFFREY JACOBSON, Drexel University College of Medicine, Philadelphia Cou
Maraviroc for HIV: Responses at 48 Weeks
Jacob Lalezari REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JACOB LALEZARI, Quest Clinical Research, San Francisco Maraviroc could be a